Non-invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics - PubMed (original) (raw)

Review

. 2020 Feb:40 Suppl 1:77-81.

doi: 10.1111/liv.14347.

Affiliations

Review

Non-invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics

Laurent Castera. Liver Int. 2020 Feb.

Abstract

Despite affecting around one-fourth of the general population worldwide, non-alcoholic fatty liver disease (NAFLD) remains a largely under-recognized disease in primary healthcare, with not more than 10% of patients diagnosed with NAFLD referred to specialists. The main challenge in clinical practice is the identification of those with advanced liver fibrosis or cirrhosis, as they are at the greatest risk of developing complications. Liver biopsy appears to be an unrealistic and unsuitable option because of the large number of high-risk patients and the well-known limitations of this technique. This has favoured the development of non-invasive tests, which have been an area of intensive research in the past decade. Transient elastography, FIB-4 and the NAFLD fibrosis score are the most extensively used and best validated tests, with summary AUROC values for detecting advanced fibrosis in NAFLD patients of 0.88, 0.84 and 0.84 respectively. Although much work remains to be done to establish cost-effective strategies for the screening for advanced fibrosis, the sequential use of non-invasive tests (serum biomarkers, then measurement of liver stiffness using transient elastography) appears to be the most promising strategy. The next step is to establish effective pathways in primary healthcare and/or diabetes clinics where most NAFLD patients are seen, to identify those who need to be referred to liver clinics for further assessment.

Keywords: NAFLD; fibrosis; liver stiffness; non-invasive; serum biomarkers; transient elastography.

© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PubMed Disclaimer

References

REFERENCES

    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
    1. Blais P, Husain N, Kramer JR, Kowalkowski M, El-Serag H, Kanwal F. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol. 2015;110(1):10-14.
    1. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557-1565.
    1. Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265-1273.
    1. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients With nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264-1281.e4.

Publication types

MeSH terms

LinkOut - more resources